G. Walmsley Graham - Net Worth and Insider Trading

G. Walmsley Graham Net Worth

The estimated net worth of G. Walmsley Graham is at least $67 Million dollars as of 2024-05-26. G. Walmsley Graham is the Director of ALX Oncology Holdings Inc and owns about 3,156,981 shares of ALX Oncology Holdings Inc (ALXO) stock worth over $42 Million. G. Walmsley Graham is the Director of Akero Therapeutics Inc and owns about 802,168 shares of Akero Therapeutics Inc (AKRO) stock worth over $15 Million. G. Walmsley Graham is also the Director of Olema Pharmaceuticals inc and owns about 1,183,114 shares of Olema Pharmaceuticals inc (OLMA) stock worth over $11 Million. Details can be seen in G. Walmsley Graham's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that G. Walmsley Graham has not made any transactions after 2023-12-08 and currently still holds the listed stock(s).

Transaction Summary of G. Walmsley Graham

To

G. Walmsley Graham Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, G. Walmsley Graham owns 4 companies in total, including ALX Oncology Holdings Inc (ALXO) , Akero Therapeutics Inc (AKRO) , and Olema Pharmaceuticals inc (OLMA) among others .

Click here to see the complete history of G. Walmsley Graham’s form 4 insider trades.

Insider Ownership Summary of G. Walmsley Graham

Ticker Comapny Transaction Date Type of Owner
ALXO ALX Oncology Holdings Inc 2020-12-14 director
AKRO Akero Therapeutics Inc 2023-12-08 director
OLMA Olema Pharmaceuticals inc 2023-12-05 director
2020-11-20 director

G. Walmsley Graham Latest Holdings Summary

G. Walmsley Graham currently owns a total of 3 stocks. Among these stocks, G. Walmsley Graham owns 3,156,981 shares of ALX Oncology Holdings Inc (ALXO) as of December 14, 2020, with a value of $42 Million and a weighting of 62.06%. G. Walmsley Graham owns 802,168 shares of Akero Therapeutics Inc (AKRO) as of December 8, 2023, with a value of $15 Million and a weighting of 21.94%. G. Walmsley Graham also owns 1,183,114 shares of Olema Pharmaceuticals inc (OLMA) as of December 5, 2023, with a value of $11 Million and a weighting of 16%.

Latest Holdings of G. Walmsley Graham

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALXO ALX Oncology Holdings Inc 2020-12-14 3,156,981 13.17 41,577,440
AKRO Akero Therapeutics Inc 2023-12-08 802,168 18.32 14,695,718
OLMA Olema Pharmaceuticals inc 2023-12-05 1,183,114 9.06 10,719,013

Holding Weightings of G. Walmsley Graham


G. Walmsley Graham Form 4 Trading Tracker

According to the SEC Form 4 filings, G. Walmsley Graham has made a total of 2 transactions in ALX Oncology Holdings Inc (ALXO) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in ALX Oncology Holdings Inc is the acquisition of 20,000 shares on December 14, 2020, which cost G. Walmsley Graham around $2 Million.

According to the SEC Form 4 filings, G. Walmsley Graham has made a total of 6 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in Akero Therapeutics Inc is the acquisition of 100,000 shares on December 8, 2023, which cost G. Walmsley Graham around $2 Million.

According to the SEC Form 4 filings, G. Walmsley Graham has made a total of 2 transactions in Olema Pharmaceuticals inc (OLMA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Olema Pharmaceuticals inc is the acquisition of 640,000 shares on December 5, 2023, which cost G. Walmsley Graham around $7 Million.

Insider Trading History of G. Walmsley Graham

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

G. Walmsley Graham Trading Performance

GuruFocus tracks the stock performance after each of G. Walmsley Graham's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by G. Walmsley Graham is 0.81%. GuruFocus also compares G. Walmsley Graham's trading performance to market benchmark return within the same time period. The performance of stocks bought by G. Walmsley Graham within 3 months outperforms 3 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how G. Walmsley Graham's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of G. Walmsley Graham

Average Return

Average return per transaction

Outperforming Transactions

1 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 15.09
Relative Return to S&P 500(%) 12.12

G. Walmsley Graham Ownership Network

Ownership Network List of G. Walmsley Graham

No Data

Ownership Network Relation of G. Walmsley Graham


G. Walmsley Graham Owned Company Details

What does ALX Oncology Holdings Inc do?

Who are the key executives at ALX Oncology Holdings Inc?

G. Walmsley Graham is the director of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include Chief Medical Officer Sophia Randolph , director & President and CEO Jaume Pons , and director & 10 percent owner Jason Lettmann .

ALX Oncology Holdings Inc (ALXO) Insider Trades Summary

Over the past 18 months, G. Walmsley Graham made no insider transaction in ALX Oncology Holdings Inc (ALXO). Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 93,208 shares made by Jaume Pons , a net sale of 10,528 shares made by Shelly Pinto , and a net sale of 13,605 shares made by Sophia Randolph .

In summary, during the past 3 months, insiders sold 102,000 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 4,400 shares, with a net sale of 97,600 shares. During the past 18 months, 118,228 shares of ALX Oncology Holdings Inc (ALXO) were sold and 4,400 shares were bought by its insiders, resulting in a net sale of 113,828 shares.

ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

ALX Oncology Holdings Inc Insider Transactions

No Available Data

G. Walmsley Graham Mailing Address

Above is the net worth, insider trading, and ownership report for G. Walmsley Graham. You might contact G. Walmsley Graham via mailing address: One Sansome Street, Suite 1650, San Francisco Ca 94104.

Discussions on G. Walmsley Graham

No discussions yet.